Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
about
Reappraisal of role of angiotensin receptor blockers in cardiovascular protectionNew insight into the molecular drug target of diabetic nephropathy.Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.New standards in hypertension and cardiovascular risk management: focus on telmisartanCombination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.Transplantation of adult recipients by single cadaveric kidneys from pediatric donors weighing < or = 25 kg can be a reliable option.Losartan in diabetic nephropathy
P2860
Q35015215-3AA21C59-1890-4795-A1E8-D76F8A726667Q35125585-103D0DDA-CBBE-4A82-9F60-48364FABFE37Q35546994-D6191770-F180-481B-A262-3DD450BA8582Q37744529-DB3D09D6-9F41-4942-82E6-4DBB7C46996BQ38105019-C343ACF5-D889-4DC9-A3D4-F20ACC9B8CD4Q46854924-6BB5962E-4B87-4384-9151-C58C6B9EAE3FQ57703074-9EC75C00-615A-4C35-8969-0B70D9D10D3D
P2860
Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Angiotensin receptor blockers ...... and cardiovascular end points.
@ast
Angiotensin receptor blockers ...... and cardiovascular end points.
@en
type
label
Angiotensin receptor blockers ...... and cardiovascular end points.
@ast
Angiotensin receptor blockers ...... and cardiovascular end points.
@en
prefLabel
Angiotensin receptor blockers ...... and cardiovascular end points.
@ast
Angiotensin receptor blockers ...... and cardiovascular end points.
@en
P2093
P1476
Angiotensin receptor blockers ...... and cardiovascular end points.
@en
P2093
Hans-Henrik Parving
Kasper Rossing
Lise Tarnow
Per K Christensen
Peter Hovind
Peter Jacobsen
P304
P356
10.1016/J.SEMNEPHROL.2003.11.003
P577
2004-03-01T00:00:00Z